ABX advanced biochemical compounds

ABX is a world-leading manufacturer and supplier of chemicals for nuclear medicine. Based in Radeberg, Germany, the company specializes in the development and production of precursors, reference standards, and reagent kits for Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT). The company operates state-of-the-art GMP-certified facilities and is a critical node in the global radiopharmaceutical supply chain. ABX is particularly renowned for its role in the development and supply of PSMA-617 precursors, which became the basis for Novartis' blockbuster radioligand therapy, Pluvicto. They also provide automated synthesis modules and custom synthesis services for global pharmaceutical companies and research institutions.